Clinical Trial: Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis

U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07243366) titled 'Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis' on Sept. 09.

Brief Summary: This study is a single-center, prospective, nonrandom, single-arm trial.

Study Start Date: Nov. 25

Study Type: INTERVENTIONAL

Condition: Refractory Myasthenia Gravis

Intervention: DRUG: CD19-CAR-NK Cells Injection

Allogeneic CD19-CAR-NK cells will be administered intravenously at a fixed dose, once every two weeks for a total treatment duration of 24 weeks.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Guangdong ProCapZoom Biosciences Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily ...